Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

TL;DR: In this article , the authors propose a method to solve the problem of image clustering in image captioning, which is based on the concept of image-based clustering of images.

TL;DR: In this paper , the authors propose a method to solve the problem of image clustering in image captioning, which is based on the concept of image-based clustering of images.

TL;DR: Ropeginterferon alfa-2b is a novel, long-acting mono-pegylated proline-IFN-alpha-2B approved for treatment of polycythemia vera in adults, regardless of thrombotic risk level or treatment history as discussed by the authors .

TL;DR: The most frequently reported grade 3 and grade 4 treatment-related adverse events were increased γ-glutamyltransferase (seven [6%] of 127 patients) and increased alanine aminotransferase (four [3].

TL;DR: It is suggested that already low levels of ropeginterferon alfa-2b are sufficient to induce significant hematologic and molecular responses and support the development of the drug in a randomized phase 3 clinical trial.

TL;DR: There is now consistent evidence showing that IFN-α is able to eliminate malignant clones harboring JAK2V617F or Calreticulin mutations, however, the molecular complexity of these diseases could hamper IFn-α efficacy, as the presence of additional non-driver mutations, like in the TET2 gene, could be associated with resistance to IFN -α.

TL;DR: In patients with advanced and transforming disease towards leukemic transformation or having transformed to acute myeloid leukemia, “triple therapy” is proposed as a novel treatment modality to be tested in clinical trials combining IFN-alpha2, DNA-hypomethylator, and ruxolitinib.